Click the photo to read more.

Framatome is a major international player in the nuclear energy market. Our employees are committed to advancing nuclear power to help meet the global ambitions to reduce carbon emissions and proud to be part of the development of medical isotopes to treat a variety of cancers.

As a company, we design, manufacture, and install components, fuel and instrumentation and control systems for nuclear power plants through a full range of services to meet reactor needs.

We are recognized for our innovative solutions and value-added technologies for designing, building, maintaining, and advancing the global nuclear fleet.

• With 14,000 employees worldwide, Framatome's passionate teams help expand nuclear technologies with an emphasis on safety and performance to help our customers achieve their economic and societal goals.
• Framatome is owned by EDF (75.5%), Mitsubishi Heavy Industries (MHI – 19.5%) and Assystem (5%).

We are committed to innovation and we believe that a diverse workforce and a culture of inclusion and equity are critical to developing the new solutions that will advance nuclear power.

Our recent growth is fueled by strategic acquisitions that have expanded our portfolio in the areas of instrumentation and controls, cybersecurity, and nuclear and engineering services.

You can learn more about who we are through our “Stories of Success” where our team members’ commitment and passion for our work and our customers’ success shines through.

In Canada, we are helping to achieve the country’s energy transformation and bring medical isotopes to patients in Canada and around the world. With Ontario offices in Pickering and Kincardine and a Quebec office in Montreal, Framatome Canada Ltd. is a major provider of services and engineering for the Canadian and global CANDU market. We are committed to developing a dynamic and innovative energy ecosystem, addressing the challenges facing the Canadian nuclear industry and transforming new ideas into reality.

Framatome Canada is proud to join with Kinectrics in creating Isogen. The joint venture works on the production of a medical isotope used for a variety of lifesaving treatments and diagnoses and advances the fight against cancer and other diseases.

We are dedicated to the communities we serve and prioritize hiring locally. 

Learn more about Framatome in North America: http://www.framatome.com/EN/businessnews-1075/who-are-we.html